<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443898</url>
  </required_header>
  <id_info>
    <org_study_id>CSFO327N2301</org_study_id>
    <nct_id>NCT00443898</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy, safety and tolerability of a topical
      formulation of terbinafine solution applied daily in patients with toenail fungus. This trial
      will study patients with mild to moderate toenail fungus disease of the big toenail and their
      responses to two treatment durations, 24 or 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes.
and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as &quot;Yes&quot; if:
Mycological cure (negative KOH and negative culture for dermatophytes) and
No residual involvement of the target toenail &quot;No&quot; if otherwise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
Mycological cure was a composite binary variable defined as &quot;Yes&quot;if :
Negative microscopy and
Negative culture for dermatophytes &quot;No&quot; if otherwise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as &quot;Yes&quot; if
Mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail &quot;No&quot; if otherwise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Assessed With Adverse Events and Serious Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed.
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle (placebo) applied once daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle (placebo) applied once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbinafine</intervention_name>
    <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>vehicle (placebo) applied once daily for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbinafine</intervention_name>
    <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>vehicle (placebo) applied once daily for 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females 12 - 75 years of age

          -  Fungal toenail infection of one or both of the large (great) toenails

          -  The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and
             non-dermatophyte] are not allowed)

        Exclusion Criteria:

          -  Target foot must not have severe plantar (moccasin) tinea pedis that would require
             systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be
             treated with terbinifine prior to baseline or at any time during the trial. Other
             topical treatments for athlete's foot may be recommended at the discretion of the
             investigator.

          -  Subjects must not have abnormalities of the nail that could prevent a normal appearing
             nail if clearing of infection is achieved

          -  No administration of systemic antifungal medications within 6 months prior to
             screening visit

          -  No application of prescription topical antifungal medications for toenail fungus
             within 3 months or other commercially available topical medications for toenail fungus
             applied directly to the toenails within 1 month prior to screening visit

          -  No professional pedicures or application of any nail polish product or nail cosmetic
             to the toenails after the screening visit

          -  Known pregnancy or lactation at time of enrollment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Boni Elewski</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Stacy Smith</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. James Swinehart</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David G. Armstrong</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kevin Terry</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anthony Puopolo</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. John Fenyk</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Joel Schlessinger</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. AnneMarie Uliasz</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Willard Niemi</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Diane Baker</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. John Barnes</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Harry Penny</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Lawrence Parish</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Cynthia Strout</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Teresa Coats</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Scott J. Ashton</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Amit Pandya</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Lawrence Harkless</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Robert Shouey</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various cities</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various cities</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Iceland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <results_first_submitted>January 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 20, 2011</results_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toenail fungus</keyword>
  <keyword>Onychomycosis</keyword>
  <keyword>Nail fungus</keyword>
  <keyword>Toenail fungal infection</keyword>
  <keyword>Tinea unguium</keyword>
  <keyword>Dermatophytes</keyword>
  <keyword>Foot dermatoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Terbinafine 24 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Vehicle 24 w</title>
          <description>vehicle (placebo) applied once daily for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Terbinafine 48 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
        </group>
        <group group_id="P4">
          <title>Vehicle 48 w</title>
          <description>vehicle (placebo) applied once daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="136"/>
                <participants group_id="P4" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terbinafine 24 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Vehicle 24 w</title>
          <description>vehicle (placebo) applied once daily for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Terbinafine 48 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
        </group>
        <group group_id="B4">
          <title>Vehicle 48 w</title>
          <description>vehicle (placebo) applied once daily for 48 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="136"/>
            <count group_id="B4" value="128"/>
            <count group_id="B5" value="518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="100"/>
                    <measurement group_id="B5" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.</title>
        <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes.
and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as
Yes” if:
Mycological cure (negative KOH and negative culture for dermatophytes) and
No residual involvement of the target toenail
No” if otherwise</description>
        <time_frame>52 weeks</time_frame>
        <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 w</title>
            <description>vehicle (placebo) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 w</title>
            <description>vehicle (placebo) applied once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.</title>
          <description>Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes.
and no residual involvement of the target toenail. The complete cure was a composite binary variable defined as
Yes” if:
Mycological cure (negative KOH and negative culture for dermatophytes) and
No residual involvement of the target toenail
No” if otherwise</description>
          <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="-2.16" upper_limit="2.19"/>
                    <measurement group_id="O2" value="0.78" lower_limit="-2.16" upper_limit="-2.16"/>
                    <measurement group_id="O3" value="1.47" lower_limit="-0.55" upper_limit="3.49"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.55" upper_limit="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.</title>
        <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
Mycological cure was a composite binary variable defined as
Yes”if :
Negative microscopy and
Negative culture for dermatophytes
No” if otherwise.</description>
        <time_frame>52 weeks</time_frame>
        <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 w</title>
            <description>vehicle (placebo) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 w</title>
            <description>vehicle (placebo) applied once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by Mycological Cure (Negative Culture and Negative KOH Microscopy) at the End of Study After Treating Patients for 24 or 48 Weeks.</title>
          <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes.
Mycological cure was a composite binary variable defined as
Yes”if :
Negative microscopy and
Negative culture for dermatophytes
No” if otherwise.</description>
          <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.32" lower_limit="-2.70" upper_limit="10.83"/>
                    <measurement group_id="O2" value="6.25" lower_limit="-2.70" upper_limit="10.83"/>
                    <measurement group_id="O3" value="15.44" lower_limit="5.54" upper_limit="19.10"/>
                    <measurement group_id="O4" value="3.13" lower_limit="5.54" upper_limit="19.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.</title>
        <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as
Yes” if
Mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail
No” if otherwise</description>
        <time_frame>52 weeks</time_frame>
        <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 w</title>
            <description>vehicle (placebo) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 w</title>
            <description>vehicle (placebo) applied once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Assessed by Clinical Efficacy at the End of Study After Treating Patients for 24 or 48 Weeks.</title>
          <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.
Clinical effectiveness was a composite binary variable defined as
Yes” if
Mycological cure (negative KOH and negative culture for dermatophytes) and
= 10% residual involvement of the target toenail
No” if otherwise</description>
          <population>All participants were included in the intention to treat (ITT) population, defined as all participants who were randomized and received study drug. The Last Observation was Carried Forward (LOCF).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59"/>
                    <measurement group_id="O2" value="2.34"/>
                    <measurement group_id="O3" value="3.68"/>
                    <measurement group_id="O4" value="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Assessed With Adverse Events and Serious Adverse Events</title>
        <description>An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed.
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.</description>
        <time_frame>52 weeks</time_frame>
        <population>Safety Population was defined as all participants who received at least one dose of study drug and had at least one post-baseline safety assessment. All except 4 participants who were randomized to the vehicle 24 w group and one participant randomized to the terbinafine 48 w group, were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine 24 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle 24 w</title>
            <description>vehicle (placebo) applied once daily for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Terbinafine 48 w</title>
            <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
          </group>
          <group group_id="O4">
            <title>Vehicle 48 w</title>
            <description>vehicle (placebo) applied once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Assessed With Adverse Events and Serious Adverse Events</title>
          <description>An adverse event (AE) is any adverse change in health or side effect that occurs while the participant is receiving the treatment or within a previously specified period of time after the treatment has been completed.
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening requires, inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage.</description>
          <population>Safety Population was defined as all participants who received at least one dose of study drug and had at least one post-baseline safety assessment. All except 4 participants who were randomized to the vehicle 24 w group and one participant randomized to the terbinafine 48 w group, were included in the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="135"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Safety Population was defined as all participants who received at least one dose of study drug and had at least one post-baseline safety assessment. All except 4 participants who were randomized to the vehicle 24 w group and one participant randomized to the terbinafine 48 w group, were included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Terbinafine 24 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Vehicle 24 w</title>
          <description>vehicle (placebo) applied once daily for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Terbinafine 48 w</title>
          <description>Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks</description>
        </group>
        <group group_id="E4">
          <title>Vehicle 48 w</title>
          <description>vehicle (placebo) applied once daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

